image credit: Adobe Stock

Traditional approaches to growth in biopharma are no longer sustainable

August 5, 2022


The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace. This has been a tough but ground-breaking period, but with this rapid rise in innovation comes risks. The industry is still relying on traditional vertical therapy areas (TAs) to drive expansion – these are no longer sustainable.

Through our recent report, Scientific innovations for more sustainable growth, we analysed over 300 M&A deals made by the world’s top 30 biopharma companies between 2010–2021. This revealed three core issues holding biopharma back – which the industry will need to overcome in order to pursue new growth paths:

Read More on Pharmaphorum